Lisa Brockway

More from our Pharma Times Interview: Research Studies and the Future of Digital Health

Our Chief Development Officer, Tom Krohn, is a pharma veteran with deep experience in R&D innovation. He was recently interviewed for an interesting article in Pharma Times on the future of digital health. Now, we’re following up with some additional thoughts from Tom on where digital health is heading, who’s leading the way, and advice he has for the industry.

Read more

Nonprofit Blogs: How to Increase Your Traffic

In the busy and often resource-constrained world of nonprofits, keeping your blog content fresh may seem like the last thing that needs to be on your list. But the fact is, blogging is a great way to engage your audience, allowing you to showcase your organization’s accomplishments while building a trusting relationship with your community, gaining free publicity, and driving traffic to your website.

Read more

#MSTrialChat: Highlights from a Twitter Chat on MS Research

Last week, we were honored to take part in the Healthline-hosted #MSTrialChat, a Twitter chat to discuss clinical trials for MS research, as well as how patients and advocacy organizations can get involved. We've reprinted the highlights below, with permission from Healthline.

Read more

How to Address Barriers to Clinical Trial Patient Recruitment

We often talk about the benefits of participating in clinical trials: patients gain access to the latest therapies in development; they contribute to future treatments and cures; and they receive personalized and attentive care. And yet, 80% of clinical trials continue to close or be delayed due to difficulty finding patients to take part.

Read more

Patients as Partners Conference 2018: Focusing on Patient Centricity

Tomorrow, we’ll be heading to Philadelphia for EyeforPharma’s annual Patients as Partners program. It’s a conference that is entirely focused on patient centricity; it will dive into how to involve patients throughout the entire drug development process to drive research efficiencies.

Read more

Antidote and the American Liver Foundation (ALF) Announce Partnership to Accelerate Liver Disease Research

Today, liver disease affects 30 million people in the US — one in 10 Americans.  And unfortunately, that number is on the rise. To address this head-on, more research is required. And of course, that involves more clinical trial volunteers.

Read more

The Special Diabetes Program: How JDRF Leads the Charge for Diabetes Research

On February 9, you may have heard that Congress renewed funding for the Special Diabetes Program (SDP), a key program that funds diabetes research through the National Institutes of Health (NIH). Our friends at JDRF were heavily involved in advocating for the SDP to be renewed, so we sat down with Cynthia Rice, JDRF’s Senior Vice President of Advocacy and Policy, to learn more.

Read more

SCOPE Summit Recap: The Best and Brightest in Clinical Operations

Earlier this month, we had the pleasure of attending the annual SCOPE Summit for Clinical Operations Executives in sunny Orlando, Florida. Once again, our team was impressed by the quality of the conference — our Chief Development Officer, Tom Krohn, described it as, “the best of the year for clinical operations leaders and service providers.” Our CEO, Pablo Graiver, said that, “SCOPE once again confirmed that it is a must-go conference.”

Read more

Tips to Achieve Patient Centricity in Trial Design

It’s no secret that the clinical trial experience is not always perfect for patients. As Paul Wicks of PatientsLikeMe said in an interview with Newsweek, “Sometimes, it’s almost as bad as dealing with Comcast or the worst airline.” Aspects such as overwhelming paperwork, appointments at inconvenient times, or tedious symptom recording can be hard for a patient to fit into an already busy schedule. It can be difficult to be a clinical trial participant — but with patient-centric trial design, the patient experience can be improved. Sponsors can ensure that the potential treatments being tested are meeting patient needs, that the endpoints being measured are meaningful to patients, and that the way they are being tested is acceptable to patients.

Read more

We’re Headed to the SCOPE Summit — Will You Be There?

It’s that time of year again — we’re heading to the SCOPE Summit in Orlando next week.

Read more